Short-term leptin treatment did not show any significant improvements on skeletal muscle, liver and adipose tissue insulin sensitivity in obese patients recently diagnosed with type 2 diabetes, experts reported in the journal Diabetes. According to the results, leptin did not fare better in reducing blood glucose, glycerol and palmitate levels in high-risk patients when compared with a placebo.

Full Story:

Related Summaries